These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8201642)

  • 1. A prospective comparison of treatments for symptomatic hot flushes following endocrine therapy for carcinoma of the prostate.
    Smith JA
    J Urol; 1994 Jul; 152(1):132-4. PubMed ID: 8201642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing hot flushes in men after prostate cancer--a systematic review.
    Frisk J
    Maturitas; 2010 Jan; 65(1):15-22. PubMed ID: 19962840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of hot flushes due to endocrine therapy for prostate carcinoma.
    Smith JA
    Oncology (Williston Park); 1996 Sep; 10(9):1319-22; discussion 1324. PubMed ID: 8882924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Megestrol acetate in relapsed carcinoma of prostate.
    Daniel F; MacLeod PM; Tyrrell CJ
    Br J Urol; 1990 Mar; 65(3):275-7. PubMed ID: 2186841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing hot flashes in men being treated for prostate cancer.
    Baum NH; Torti DC
    Geriatrics; 2007 Nov; 62(11):18-21. PubMed ID: 17999566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic options in treatment of advanced carcinoma of the prostate.
    Venner PM
    Semin Oncol; 1990 Dec; 17(6 Suppl 9):73-7. PubMed ID: 2259929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-treatment testosterone levels: significance in androgen deprivation therapy.
    Hickey D; Todd B; Soloway MS
    J Urol; 1986 Nov; 136(5):1038-40. PubMed ID: 3095566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Megestrol acetate for the prevention of hot flashes.
    Loprinzi CL; Michalak JC; Quella SK; O'Fallon JR; Hatfield AK; Nelimark RA; Dose AM; Fischer T; Johnson C; Klatt NE
    N Engl J Med; 1994 Aug; 331(6):347-52. PubMed ID: 8028614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of castration compared with total androgen blockade on tissue dihydrotestosterone (DHT) concentration in benign prostatic hyperplasia (BPH).
    Geller J; Albert J
    Urol Res; 1987; 15(3):151-3. PubMed ID: 3629749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Megestrol acetate plus low-dose estrogen in the management of advanced prostatic carcinoma.
    Geller J
    Urol Clin North Am; 1991 Feb; 18(1):83-91. PubMed ID: 1825145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative effectiveness of alternative androgen withdrawal therapies in initiating regression of rat prostate.
    Rennie PS; Bruchovsky N; Goldenberg SL; Lawson D; Fletcher T; Foekens JA
    J Urol; 1988 Jun; 139(6):1337-42. PubMed ID: 2967378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Megestrol acetate in the treatment of metastatic carcinoma of the prostate.
    Venner P
    Oncology; 1992; 49 Suppl 2():22-7. PubMed ID: 1461622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newer methods of hormonal therapy for prostate cancer.
    Soloway MS
    Urology; 1984 Nov; 24(5 Suppl):30-8. PubMed ID: 6437034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormonal management of advanced adenocarcinoma of the prostate.
    Miles BJ
    Henry Ford Hosp Med J; 1989; 37(1):16-8. PubMed ID: 2670839
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial.
    Irani J; Salomon L; Oba R; Bouchard P; Mottet N
    Lancet Oncol; 2010 Feb; 11(2):147-54. PubMed ID: 19963436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hot flushes in men after surgical or pharmacologic castration].
    Aubert J; Vigouroux V; Doré B
    Prog Urol; 1995 Sep; 5(4):507-9. PubMed ID: 7581499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical castration using megestrol acetate and minidose estrogen.
    Johnson DE; Babaian RJ; Swanson DA; von Eschenbach AC; Wishnow KI; Tenney D
    Urology; 1988 May; 31(5):371-4. PubMed ID: 3284149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hot flushes: mechanism and prevention.
    Radlmaier A; Neumann F; Bormacher K
    Prog Clin Biol Res; 1989; 303():89. PubMed ID: 2675021
    [No Abstract]   [Full Text] [Related]  

  • 19. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer.
    Seidman AD; Scher HI; Petrylak D; Dershaw DD; Curley T
    J Urol; 1992 Mar; 147(3 Pt 2):931-4. PubMed ID: 1371564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of prostatic cancer. Newer forms of androgen deprivation.
    Soloway MS
    Postgrad Med; 1986 Jul; 80(1):249-52, 257-8. PubMed ID: 2941729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.